News
Amid Boston Overdose Crisis, a Pair of Harvard Students Are Bringing Narcan to the Red Line
News
At First Cambridge City Council Election Forum, Candidates Clash Over Building Emissions
News
Harvard’s Updated Sustainability Plan Garners Optimistic Responses from Student Climate Activists
News
‘Sunroof’ Singer Nicky Youre Lights Up Harvard Yard at Crimson Jam
News
‘The Architect of the Whole Plan’: Harvard Law Graduate Ken Chesebro’s Path to Jan. 6
The dean of the Yale Medical School, whose connections with a major pharmaceutical company were disclosed in recent congressional hearings, will leave Yale to become the president of Memorial-Sloan Kettering Cancer Institute in New York.
Dr. Lewis Thomas, the Yale dean, will resign on July 1, Yale President Kingman Brewster Jr. announced last week.
Thomas was appointed dean last July 1. The briefness of his tenure raised speculation that his resignation was related to the disclosure in congressional hearings last October that Thomas and Robert H. Ebert, dean of the Harvard Medical School, were both paid consultants to the Squibb Corporation, a major pharmaceutical manufacturer.
No Relation
Doubts about a possible conflict of nterest were brought up after the disclosure.
"There is no relation whatsoever between the Squibb thing and my resignation," Thomas, reached at his home in Connecticut, said yesterday.
A spokesman for The Yale Daily News said yesterday that Thomas's new job would be much more prestigious and that his salary would be substantially higher than his present one.
Leading Job
Steve Kezerian, director of Yale's News Bureau, said last week that Thomas' new position will be "one of the leading jobs in the country involving cancer research," the Daily News reported.
President Brewster is naming a special faculty committee to help him in the search for a new dean. However, no obvious candidates have been mentioned for the position.
Thomas came to Yale in 1969 as the chairman of the Department of Pathology.
Want to keep up with breaking news? Subscribe to our email newsletter.